Back to top
more

CareDx (CDNA)

(Delayed Data from NSDQ)

$7.56 USD

7.56
555,366

-0.42 (-5.26%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $7.56 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CDNA

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

CareDx, Inc. [CDNA]

Reports for Purchase

Showing records 61 - 80 ( 80 total )

Company: CareDx, Inc.

Industry: Medical Services

Record: 61

08/02/2019

Company Report

Pages: 6

2Q19 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 62

05/09/2019

Company Report

Pages: 6

1Q19 Financial Results Reported; Upgrade to Buy; Raise Price Target to $43

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 63

03/07/2019

Company Report

Pages: 5

2018 Financial Results Reported; Reiterate Neutral and Raise Price Target to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 64

02/04/2019

Company Report

Pages: 5

No Near-Term Kidney Transplant Testing Competitive Threat, in our View; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 65

01/10/2019

Company Report

Pages: 5

Preliminary 2018 Financial Results Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 66

12/21/2018

Company Report

Pages: 5

New AlloSure Clinical Utility Data Published; Financing Completed; Reiterate Neutral and Lower Price Target to $27

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 67

11/12/2018

Company Report

Pages: 6

3Q18 Financial Results; 2018 Guidance Increased; Reiterate Neutral and Raise Price Target to $28

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 68

10/03/2018

Company Report

Pages: 5

Illumina-Partnered AlloSeq Suite Launching in 2019; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 69

09/18/2018

Company Report

Pages: 6

HeartCare Registry Launched; Revenue Projections Increased; Reiterate Neutral and Raising Price Target to $22

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 70

08/10/2018

Company Report

Pages: 6

2Q18 Revenue up 48% YoY; Guidance Raised; Reiterate Neutral and Raising Price Target to $17

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 71

06/28/2018

Company Report

Pages: 5

Commercial Prospects of Competing Kidney Transplant Test Unclear; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 72

06/22/2018

Company Report

Pages: 5

A Competing Post Kidney Transplant Test May Enter the Market in 2019; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 73

06/19/2018

Company Report

Pages: 5

Physician Support for AlloSure; Downgrading to Neutral on Valuation; Raising Price Target to $15

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 74

05/11/2018

Company Report

Pages: 6

2018 1Q Results Reported; Reiterate Buy and Raising Price Target to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 75

04/12/2018

Company Report

Pages: 5

AlloMap and AlloSure-Heart Combination Launched; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 76

04/02/2018

Company Report

Pages: 5

Debt Conversion Completed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 77

03/23/2018

Company Report

Pages: 6

2017 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 78

03/02/2018

Company Report

Pages: 6

Debt Refinanced With Perceptive Advisors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 79

01/31/2018

Company Report

Pages: 5

AlloSure to Drive Revenue Growth towards Profitability in 2018; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: CareDx, Inc.

Industry: Medical Services

Record: 80

11/27/2017

Company Report

Pages: 24

Revolutionizing Transplant Monitoring Non- Invasively; Initiating at Buy With $12 Price Target

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 75.00

Research Provided by a Third Party